Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367251 | 0.84 | SIGMAR1 (0.61) | SIGMAR1KCNA3PPARGPPARA | |
| SCHEMBL5535410 | 0.84 | SIGMAR1 (0.46) | SIGMAR1KCNA3PPARGPPARAS1PR1 | |
| SCHEMBL6373460 | 0.84 | PARP1 (0.50) | SIGMAR1KCNA3PPARGPPARADRD2 | |
| SCHEMBL5544450 | 0.83 | SIGMAR1 (0.48) | SIGMAR1PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL5542216 | 0.82 | PPARG (0.47) | SIGMAR1KCNA3PPARGPPARAS1PR1 | |
| SCHEMBL6372796 | 0.82 | SIGMAR1 (0.58) | SIGMAR1KCNA3DRD2 | |
| SCHEMBL5544488 | 0.82 | SIGMAR1 (0.47) | SIGMAR1PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL5535869 | 0.81 | PPARG (0.48) | SIGMAR1PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL14438052 | 0.81 | PPARG (0.51) | SIGMAR1PPARGPPARA | |
| SCHEMBL6434881 | 0.81 | SIGMAR1 (0.57) | SIGMAR1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | SIGMAR1 3797/4885KCNA3 3374/4885PPARG 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.